Nerlynx — Medical Mutual
Continuation of Therapy
Initial criteria
- Patient has been started on Nerlynx for an indication addressed as an approval in this document
Reauthorization criteria
- Continuation of therapy may be granted to complete 1 full year of treatment for HER2-overexpressed/amplified Breast Cancer; if one full year has been given, approval cannot be granted
- For other approvable indications, extended approval is 1 year
Approval duration
1 year